Article Text

PDF
Paroxysmal hemicrania responding to topiramate
  1. A S Cohen,
  2. P J Goadsby
  1. Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
  1. Correspondence to:
 P J Goadsby
 Institute of Neurology, Queen Square, London WC1N 3BG, UK; peterg{at}ion.ucl.ac.uk

Abstract

Chronic paroxysmal hemicrania (CPH) is a rare primary headache syndrome, which is classified along with cluster headache and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) as a trigeminal autonomic cephalalgia. CPH is exquisitely responsive to indomethacin so much so that the response is one of the current diagnostic criteria. The case of a patient with CPH, who had marked epigastric symptoms with indomethacin treatment and responded well to topiramate 150 mg daily, is reported. Cessation of topiramate caused return of episodes, and the response has persisted for 2 years. Topiramate may be a treatment option in CPH.

  • COX, cyclooxygenase
  • CPH, chronic paroxysmal hemicrania
  • SUNCT, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • Informed consent was obtained for publication of the patient’s details described in this report.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.